Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | TK1 | P04183 | 4/20 | 0.63 |
| ▸ | TYMS | P04818 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622019 | 0.91 | POLB (0.63) | POLBTK1TYMS | |
| SCHEMBL16359946 | 0.91 | TK1 (0.69) | POLBTK1TYMS | |
| SCHEMBL887852 | 0.91 | TK1 (0.69) | POLBTK1TYMS | |
| SCHEMBL6829899 | 0.90 | POLB (0.64) | POLBTK1TYMS | |
| SCHEMBL1517627 | 0.90 | POLB (0.64) | POLBTK1TYMS | |
| SCHEMBL7626234 | 0.90 | POLB (0.64) | POLBTK1TYMS | |
| SCHEMBL8470853 | 0.89 | TK1 (0.64) | POLBTK1TYMS | |
| SCHEMBL6046227 | 0.89 | POLB (0.66) | POLBTK1TYMS | |
| SCHEMBL19101672 | 0.89 | POLB (0.66) | POLBTK1TYMS | |
| SCHEMBL4809523 | 0.88 | POLB (0.68) | POLBTK1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625872-B2 | Branched immunomodulatory compounds and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1625140-A4 | BRANCHED IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME | DYNAVAX TECH CORP (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1625140-A2 | BRANCHED IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME | Dynavax Technologies Corporation (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004058159-A2 | BRANCHED IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | DYNAVAX TECHNOLOGIES CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040136948-A1 | Branched immunomodulatory compounds and methods of using the same | IFNG, ICOS, IL2 | POLB 2095/4885TK1 2894/4885TYMS 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.